13F Pro quality score
Rank #2,836 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Silo Pharma, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $72.1K | $-4.2M | — |
| FY 2024 | 10-K | $72.1K | $-4.4M | — |
| FY 2023 | 10-K | $72.1K | $-3.7M | — |
| FY 2022 | 10-K | $72.1K | $-3.9M | — |
| FY 2020 | 10-K/A | $40.9K | $-3.0M | — |
| FY 2019 | 10-K/A | $40.6K | $-1.0M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Silo Pharma, Inc. (SILO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SILO at 13.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,836 of 2,925 stocks — the bottom half of the AI-ranked universe. SILO trades on the Nasdaq exchange and files with the SEC under CIK 1514183. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SILO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Silo Pharma, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1514183 →